4.6(top 5%)
impact factor
3.9K(top 5%)
papers
104.0K(top 5%)
citations
114(top 5%)
h-index
5.0(top 5%)
impact factor
4.5K
all documents
108.6K
doc citations
153(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015Expert Opinion on Investigational Drugs2017469
2Glioblastoma multiforme: a review of where we have been and where we are goingExpert Opinion on Investigational Drugs2009432
3Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatmentExpert Opinion on Investigational Drugs2006360
4Targeting STAT3 in cancer: how successful are we?Expert Opinion on Investigational Drugs2009357
5Pregabalin: a new anxiolyticExpert Opinion on Investigational Drugs2003291
6Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphomaExpert Opinion on Investigational Drugs2007289
7Rutin: therapeutic potential and recent advances in drug deliveryExpert Opinion on Investigational Drugs2013289
8The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancerExpert Opinion on Investigational Drugs2009279
9Histone deacetylase inhibitors: discovery and development as anticancer agentsExpert Opinion on Investigational Drugs2005278
10Berberine: a potential phytochemical with multispectrum therapeutic activitiesExpert Opinion on Investigational Drugs2010265
11Therapeutic applications of carbon monoxide-releasing moleculesExpert Opinion on Investigational Drugs2005261
12Ebselen: prospective therapy for cerebral ischaemiaExpert Opinion on Investigational Drugs2000253
13The clinical development of histone deacetylase inhibitors as targeted anticancer drugsExpert Opinion on Investigational Drugs2010253
14Squalene: potential chemopreventive agentExpert Opinion on Investigational Drugs2000251
15Targeting the transforming growth factor-β signaling pathway in human cancerExpert Opinion on Investigational Drugs2010239
16Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitusExpert Opinion on Investigational Drugs2001236
17EscitalopramExpert Opinion on Investigational Drugs2002230
18Terpenoids: natural products for cancer therapyExpert Opinion on Investigational Drugs2012230
19A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)Expert Opinion on Investigational Drugs2009228
20Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatinExpert Opinion on Investigational Drugs2009226
21PTP1B inhibitors as potential therapeutics in the treatment of Type 2 diabetes and obesityExpert Opinion on Investigational Drugs2003224
22Antioxidants as treatment for neurodegenerative disordersExpert Opinion on Investigational Drugs2002215
23Histone deacetylase inhibitors: from target to clinical trialsExpert Opinion on Investigational Drugs2002213
24A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseasesExpert Opinion on Investigational Drugs2011212
25Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular diseaseExpert Opinion on Investigational Drugs2015211
26Akt inhibitors in clinical development for the treatment of cancerExpert Opinion on Investigational Drugs2010202
27The immunotherapeutic potential of melatoninExpert Opinion on Investigational Drugs2001199
28Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetesExpert Opinion on Investigational Drugs2003197
29Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumorsExpert Opinion on Investigational Drugs2018195
30Histone deacetylase inhibitors in cancer therapyExpert Opinion on Investigational Drugs2007193
31Do STAT3 inhibitors have potential in the future for cancer therapy?Expert Opinion on Investigational Drugs2017191
32Zaleplon - a review of a novel sedative hypnotic used in the treatment of insomniaExpert Opinion on Investigational Drugs2000188
33Antimicrobial properties of porphyrinsExpert Opinion on Investigational Drugs2001188
34Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and developmentExpert Opinion on Investigational Drugs2000187
35Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancerExpert Opinion on Investigational Drugs2009187
36Mechanism of action of the oxazolidinone antibacterial agentsExpert Opinion on Investigational Drugs1999184
37Novel therapeutic usage of low-dose doxepin hydrochlorideExpert Opinion on Investigational Drugs2007182
38Daptomycin: a novel agent for Gram-positive infectionsExpert Opinion on Investigational Drugs1999180
39The therapeutic potential of flavonoidsExpert Opinion on Investigational Drugs2000178
40Combretastatin A4 phosphate: background and current clinical statusExpert Opinion on Investigational Drugs2004178
41Cathepsin K inhibitors for osteoporosis and potential off-target effectsExpert Opinion on Investigational Drugs2009177
42Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?Expert Opinion on Investigational Drugs2004176
43Aldose reductase inhibitors: therapeutic implications for diabetic complicationsExpert Opinion on Investigational Drugs1999174
44Cilengitide: an integrin-targeting arginine–glycine–aspartic acid peptide with promising activity for glioblastoma multiformeExpert Opinion on Investigational Drugs2008174
45Targeting Mcl-1 for the therapy of cancerExpert Opinion on Investigational Drugs2011173
46Protein kinase C inhibitors as novel anticancer drugsExpert Opinion on Investigational Drugs2001167
47Indisulam: an anticancer sulfonamide in clinical developmentExpert Opinion on Investigational Drugs2003166
48Duloxetine: a serotonin-noradrenaline re-uptake inhibitor for the treatment of stress urinary incontinenceExpert Opinion on Investigational Drugs2003165
49The benzodiazepine binding site of GABAAreceptors as a target for the development of novel anxiolyticsExpert Opinion on Investigational Drugs2005163
50Triclabendazole for the treatment of fascioliasis and paragonimiasisExpert Opinion on Investigational Drugs2005162